Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...
AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...
IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...
The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...
Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...
Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but Europe's drug industry has already said it will not be enough to keep the sector ...
A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...
Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart. In final draft guidance (PDF), NICE ...
According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...
Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...
Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results